Index

adolescents
  awareness of diagnosis, 275–9
  clinical trials, US, 230
  support services, 260–1
adoption, 168–9
Africa, vertical transmission rates, 6
AIDS
  1993 total cases, Europe, 1–2
  at presentation, 135
  defining events, 132–3, 177–9
  indicators see HIV-related symptoms; specific diseases
  surveillance [USA], 22–3
AIDS, children
  indicator diseases, 39
  USA
    by metropolitan areas, 27
    by mode of transmission, 24–5
    seroprevalence data, 27–30
AIDS, women
  USA
    by mode of transmission, 23–5
    by race/ethnicity and mode of transmission, 26
    seroprevalence data, 27–30
AIDS Clinical Trials Group (ACTG)
  current agenda, 222
  history, 222
  perinatal trials, 223–30
  research priorities, 223
amniocentesis, 156
anaemia, 181, 207
animal models of retroviral infection, 110–11
antenatal care, 146–8
  counselling, 156
  invasive procedures, avoidance, 156
  reportable symptoms, list, 147
  antenatal testing, 140–2, 146–7
  criteria, 141
  antibodies to HIV see immunoglobulins
antiretroviral therapy, 205–20
  combination therapies, 213–14, 228
  immune-based therapies, 215
  management guidelines, 216–17
  non-nucleoside reverse transcriptase inhibitors, 214
  other drugs, 214–15
  potential targets, 207
  protease inhibitors, 214
  trials [USA], 224–8
  vaccine therapy, 216, 229–30
  see also didanosine, dideoxycytidine; zidovudine
assays for HIV infection, 83–95
assessment, nurse's role, 237–8
3'-azido-3'-deoxythymidine see zidovudine
azithromycin-atovaquone, MOPP Study, 229
AZT see zidovudine
bacterial infections
  AIDS-defining, 132–3, 177–9
  control, postnatal care, 150
  gastrointestinal, 186–7
  non-AIDS, 131
  predictive value, 60–1
  BCG, in HIV-infected newborns, 157–8
  benzalkonium chloride, 13
  bereavement see death
  BHAP compounds, 214
  bimodal disease pattern
  hypothesis, 77
  incubation period for AIDS, 42, 114
  birth see delivery
  bites, HIV transmission, 38
  blood, safety measures, 38, 151, 243, 248, 265–7
  blood and blood products
    purity factors, 196
    transfusion, USA, 35–6
<table>
<thead>
<tr>
<th>Index</th>
<th>307</th>
</tr>
</thead>
<tbody>
<tr>
<td>nurse’s role, 237</td>
<td></td>
</tr>
<tr>
<td>talking with the dying child, 270–82</td>
<td></td>
</tr>
<tr>
<td>classification of HIV infection, 52–71</td>
<td></td>
</tr>
<tr>
<td>current CDC system, 53–4 problems, 54–5</td>
<td></td>
</tr>
</tbody>
</table>
death (cont.)
  family support, 279–80
  patterns of mourning, 289–90
  secure environment for, 294–6
  protection from, 295
  talking with the dying child, 270–82
  definitions, paediatric AIDS, 63–4
  delivery
  caesarean section, 10, 12, 148–9
  infection during, 105
  obstetric factors, 144, 148–9
  postnatal care, 149–50
  dementia, incidence, 133
  diagnosis of HIV infection, 5–6, 80–103
  CDC classification, 53–4
  clinical staging, 53
  criteria, 53
  detection assays, 83–90
  ‘indeterminate status’ infants, 162–3
  new system, considerations for, 55–63
  persistence of maternally acquired antibodies, 6
  diarrhoea, 186–7
  prognostic value, 61
  didanosine [dideoxynosine], 118
  US paediatric treatment trials, 225, 227–8
  dideoxycytidine [zalcitabine], 118, 212–13
  combination therapies, 214, 228
  dose-limiting cytotoxicity, 212
  pharmacokinetic data, 213
  US paediatric treatment trials, 228
  dideoxynosine, see didanosine;
  nucleoside analogue antivirals
  diet, 303
  drug-related problems, see injection drug use
ELISA, 86, 91
ELISPOT, 93
sensitivity and specificity of assays, 88
encephalopathy, 179–80
marker of disease progression, 72–5
epidemiology, USA, 22–38
Europe
AIDS, 1993 total, 1–2
vertical transmission rates, 6, 10
European Collaborative Study
prognoses, 74, 155
vertical transmission rates, 6, 10
failure-to-thrive, 187–8
family support, 251–63
dying child, 279–80
effect of HIV in family, 252–4
models of care, 254–5, 256–9
one-stop clinics, 256–7
preschool and respite care, 257
substitute care programmes, 257–9
nurse’s role, 238, 245–6
older children, 260–2
planning and coordinating care, 255–6
schooling, 169–72, 259–60
social and demographic trends, 251–2,
257–9
training, 258, 260
fetus
HIV infection in utero, 105–6
immune system development, 104–6
follow-up
long-term, nurse’s role, 240–2
see also family support
follow-up care of infant, 155–76
clinical and laboratory markers, 164
HIV testing, 167–9
procedure, 164
schedule, 160–1, 162
foster care, 168, 258
case history, 298–305
fungal infections, prognosis, 61
gastrointestinal symptoms, 186–7
genetically engineered fragment,
post-infection immunisation, 120
genital neoplasms, 134–5
genital tract infections, 131–3
gestation, HIV infection in utero, 105–6
Giardia lamblia, 186
gp120 viral protein assay, 92
grandparents as carers, 245, 257–9
granulocytopenia, 207
grief, patterns of mourning, 289–90
growth, predictive value, 59
growth retardation, malnutrition, 187–8
haematological disorders, 128, 180–1
predictive value, 58–9
haemophilia and HIV infection, 192–204
care requirements, 199–201
children of HIV-infected haemophilic
fathers, 202
comparison with other groups, 194–7
Europe, 2
extent of problem, 193–4
haemophilia B [Christmas disease], 193
incidence, 193
progression of disease, 194–7
transmission and safety, 201–2
when to tell, 197–9
Haemophilus influenzae infection, 131,
158, 180
immunisation, 158
hepatitis, predictive value, 58
hepatomegaly, predictive value, 57
Index

herpes simplex, 133
HIV
asymptomatic replication, 108–9
detection assays, 83–90
life cycle, 81–3
targets for antiretroviral therapy, 207
HIV infection
asymptomatic HIV replication, 108–9
comparison with drug-related problems, 129–30
follow-up care, 155–76
immunity/elimination of virus, 116
‘indeterminate status’ infants, 162–3
nurse’s role, 235–50
a parent’s view, 298–305
pathogenesis, 106–11
prevalence
Europe, 2–5
London, 4
newborns, 3
by screening programmes, 3
prevention strategies, 43
primary infection, 107–8
quantitation, 90–1, 119
vs seroreversion, non-specific signs and symptoms, 41
surveillance methods, 30–2
HIV testing, 140–2, 146–7, 167
consent, 167
diagnostic purposes, 167
follow-up care, 167–9
place in foster care and adoption, 168–9
school placement, 169–73
sexual abuse, 168
HIV-2, vertical transmission rates, 6–7
HIV-infected woman, 124–39
clinical problems
drug-related, 127–8
HIV problems, 128–30
infections (AIDS-defining events), 132–3, 177–9
infections [non-AIDS], 131
management principles, 135–7
neoplasms, 153–5
non-AIDS mortality, 132
pregnancy, 124–5
progression to AIDS, 124–6
survival after AIDS diagnosis, 126–7
HIV-related symptoms, 177–91
AIDS-defining events, 132–3, 177–9
CNS manifestations, 179–81
failure-to-thrive, 187–8
gastrointestinal symptoms, 186–7
haematological manifestations, 181
lymphoid pulmonary lesions, 183–5
recurrent infections, 177–9
respiratory manifestations, 181–3
HIV-specific antibody, in vitro production, 92–3
HLA haplotype, 111
homo/bisexuals, Kaposi’s sarcoma, 132, 133
hospital care, 239–40
IDU see injection drug use
immune response
anti-HIV response, 116
at birth, 105
immune modulatory therapy, 159
passive immunisation, 14
immune system, ontogeny, 104–6
immune-based interventions, 215, 225–6
US paediatric treatment trials, 225–6
immunisation
active, 14, 225–6
passive, 6, 14, 215, 226
and prophylaxis, 157–60
suboptimal responses, 158–9
see also vaccines
immunodeficiency see clinical markers of immunodeficiency
immunoglobulins
hyper gammaglobulinaemia, 109
hyp er immunoglobulinaemia, 113
hypogammaglobulinaemia, 113
IgA antibody
HIV-specific, 92, 112
sensitivity and specificity of assays, 88
IgG antibody
HIV-specific, search for, 92
sensitivity and specificity of assays, 88
IgM antibody, HIV-specific, 91–2, 112
intravenous, indications, 178–9
levels, changes, 113–14
maternally acquired, passive, 6, 14
immunological changes in HIV, 111–17
lymphocyte subpopulation markers, 111–13
paediatric HIV infection, 104–23
recurrent infections, 177–9
immunological classification, 61–3
in vitro production of HIV-specific antibody, 92–3
incubation period for AIDS
bimodal distribution, 42, 114
prevalence of non-specific signs and symptoms in vertical transmission, 42
‘indeterminate status’ infants, 162–3
indicator infections, 59, 132–3, 177–9
infection control, list of safety measures, 151
injection drug use
clinical problems, 127–8
comparison with HIV-related problems, 129–30
interferons, 215
intrapartum transmission, 5
Isospora belli, 186
Italian register, predictive value, 56–7, 62
IVAP, sensitivity and specificity of assays, 88
Jakob–Creutzfeldt disease, 180
Kaposi’s sarcoma
at presentation, 132
in homo/bisexuals, 132, 133
incidence, 132–3
transmission, 134
lymphadenopathy, and survival, 57
lymphoid interstitial pneumonitis [LIP] data, 75, 183–5
diagnosis, 184
predictive value, 58, 183–5
lymphoid pulmonary lesions, 183–5
lymphoma, malignant, 134
malnutrition, 187–8
measles, and HIV infection, 159
meningitis, Haemophilus influenzae infection, 158, 180
β2-microglobulin, 109
Microsporidium, 186
models of care, family support, 254–5, 256–9
MOPP Study, 229
mother–child transmission see vertical transmission
multidisciplinary team, specialist services, 243–4, 304
Mycobacterium avium complex, occurrence, US data, 39–40
Mycobacterium avium intracellularare, 133, 186
prophylaxis study, 229
national AIDS registries, 72
natural history of HIV infection, 72–9
developing countries, 75–6
industrialised countries, 72–5
natural killer cells, defects, 116–17
neonates
actions required in neonatal period, 158
patterns of HIV infection, 93–5
prevalence of HIV infection, 1–5
screening, 126

Index

spread of virus to PBMC in first weeks, 95
neoplasia, cervical, 134–5
neopterin, 109
nephropathy, predictive value, 58
neurological disease, predictive value, 59
neutrophils, defects, 117
nevirapine, 214
US paediatric treatment trials, 225
newborns see neonates
non-nucleoside reverse transcriptase inhibitors, 214
reduction of vertical transmission, 13, 14
nonoxynol-9, 12
nucleoside analogue antivirals, CD4 count, 115, 118–19
nurse’s role, 235–50
assessment, 237–8
caring for family, 238–9
child protection, 244–5
chronic illness, 237
confidentiality, 243
family support, 238, 245–6
HIV in the community, 244, 245–6
long-term follow-up, 240–2
nursing at home, 239
nursing in community, 239–40
personal safety, 248
professional development, 247–8
research, 248–9
specialist services, 243–4
terminal care, 246–7
uptake of services, 242
nutritional support, 188–9

obstetric factors
affecting vertical transmission, 144–5
at delivery, 148–9
oesophagitis, 131, 132, 133, 178
one-stop clinics, family support, 256–7
orphans
numbers, USA, 35
social pressures, 165

p24 antigen assay, 89–90
PBMC, spread of virus in first weeks, 95
sensitivity and specificity, 88
p24-antigenemia, 9, 76, 155
paediatric care see follow-up care;
multidisciplinary team; nurse’s role; Pediatric ACTG
parental view of HIV infection, 298–305
parotitis, and survival, 57
pathogenesis of HIV infection, 106–11
clinical immunodeficiency, 109–11
primary infection, 107–8
Index

PCP see Pneumocystis carinii pneumonia

Pediatric ACTG
 research priorities, 223
 US paediatric treatment trials, 223–8
 pelvic inflammatory disease, 131
 pentamidine therapy, 183
 peribronchial lymphoid hyperplasia (PLH), 183
 perinatal transmission
 prophylaxis, 215
 see also vertical transmission
 perinatal trials
 US paediatric treatment trials, 223–8
 vertical transmission, 223–8

Pneumocystis carinii pneumonia, 159–60
 clinical features, 128, 181–3
 fulminant paediatric course, 117
 predictive value, 42–3, 59
 CD4 counts, 117
 presentation, 159–60
 prevention strategies, 61–2, 159–60, 182–3
 MOPPS study, 229
 when to start, 161
 therapy, 183
 trimethoprim–sulphamethoxazole therapy, 179
 pneumonitis see lymphoid interstitial pneumonitis (LIP)
 poliomyelitis, immunisation, 158
 polymerase chain reaction, 83–7
 postnatal care, 149–50
 infection control, 150
 prediction of disease progression, 76
 prediction of survival time, PEP, 42–3
 pregnancy, HIV-infected woman, 124–5, 140–54
 antenatal care, 146–8
 antenatal testing, 140–2, 146–8
 criteria, 141
 effect on maternal disease, 142–3
 follow-up, 155–76
 outcome, 145–6
 and progression to AIDS, 124–6
 trial of zidovudine, 209–10
 vertical transmission, 143–5
 prematurity, risk factor in vertical transmission, 9
 preschool and respite care, 257
 presentation for care, women, 126
 prevalence of HIV infection, 1–5
 in newborns, Italy, 5
 USA, 6, 21–38
 prevention of HIV infection
 antenatal period, 155–6
 testing of pregnant women, 43

immunisation and prophylaxis, 157–60
 late tests, 43
 neonatal period, 156–7
 perinatal period, 215
 safety measures, 151
 see also vertical transmission
 progression of disease, 72–9
 encephalopathy, 72–5
 patterns of, 74
 progressive multifocal leucoencephalopathy (PML), 180
 prospective studies, industrialised/developing countries, 72–6
 protease inhibitors, 214
 pyridinone, 214

quantitation of HIV infection, 90–1
 viral load, 119
 recurrent infections, 177–9
 research, nurse’s role, 248–9
 respiratory manifestations of HIV infection, 75, 181–5
 respiratory syncytial virus (RSV), 184
 respite care, 257
 retrovir see zidovudine
 reverse transcriptase inhibitors, 13, 14, 214
 Rifabutin, 40

risk factors for transmission of HIV see vertical transmission

safety measures, 38, 243
 list for infection control, 151
 personal safety, 248
 school placement, 265–7
 Salmonella typhimurium infection, 131
 school placement, 169–71, 259–60, 264–9, 264–82
 confidentiality, 243, 267–8
 procedure, 172
 safety measures, 265–7
 screening programmes, prevalence of AIDS, 3
 seroconversion
 during pregnancy, 8–9
 following seroreversion, 165
 seroconversion data, USA, 27–30
 seroconversion vs HIV infection, non-specific signs and symptoms, 41
 positive assays, 55–6
 sexual abuse, 168
 HIV transmission, USA, 36–7
 silent infections, 55–6
 SIV, asymptomatic replication, 108–9
 smoking, 136
Index

social and demographic trends, family support, 251–2
social services
substitute care programmes, 257–9
see also family support
specialist services, nurse’s role, 243–4
spleenomegaly, predictive value, 57
stavudine, US paediatric treatment trials, 224
STDS, mucosal lesions, intrapartum infection, 8
Streptococcus pneumoniae infection, 131
surrogate markers of clinical immunodeficiency, 117–20
ideal markers, 118
surveillance methods, USA
AIDS, 22–3
HIV, 30–2
survival, post-AIDS, 126–7
syncytium producing viruses, 96–7

T lymphocytes
CD categories see CD T lymphocytes functional evaluation, 115
subpopulation markers, 111–13
terminal care, 166–7
nurse’s role, 246–7
talking with the dying child, 270–82
thrombocytopenia, 128, 180–1
thymic cells, viral burden, 96
TIBO, 214
timing of HIV infection, 10–11, 111–13
toxoplasmosis
at presentation, 133
genital transmission, 180
training of carers, 258, 260
transmission modes
care settings, 37
trauma, 38
USA
blood and blood products transfusion, 35–6
by year of diagnosis, 25
Trichomonas infection, 131
trimethoprim–sulphamethoxazole (TSM-SMX) therapy, 179, 183
MOPP Study, 229
tuberculosis
at presentation, 132
and HIV infection, 43
tumour necrosis factor, 215

UK, prevalence of HIV infection in newborns, 5
uptake of services, nurse’s role, 242
USA
AIDS as leading cause of death in, 221
blood and blood products transfusion, 35–6
epidemiology, 22–38
incidence, 21
women, 21
mortality, 21
seroprevalence data, 27–30
vertical transmission rates, 6
US paediatric treatment trials, 221–34
adolescent trials, 230
current scientific agenda, 222
history, 222
immune-based interventions, 225–6
perinatal trials, 223–30
research priorities, 223
uterine transmission see vertical transmission

vaccines
HIV envelope, 225
therapy, 216
see also immunisation
vertical transmission, 5
indicator diseases, 39, 132–3, 177–9
interruption, 146
interventions to reduce, 12–15
virucidal agents, 12–13
non-specific signs and symptoms, AIDS vs not AIDS, 42
perinatal transmission, 215
perinatal trials, 223–8
prevalence of non-specific signs and symptoms, 42
rates, 6–7, 143–4
estimates, 7
risk factors, 7–10
breastfeeding, 11–12, 144, 149
caesarean section, 10, 12, 148–9
chorioamnionitis, 9–10
low CD4/CD8 ratio, 9, 155
mothers with AIDS, 9
obstetric factors, 144–5, 148–9
other diseases, 8
other STDs, 8, 10
p24-antigenaemia, 9, 76, 155
prematurity, 9
reduction, 9
viral load and infectivity, 8
virus type, 8
see also breastfeeding
route, 143–4
time of infection, 10–11, 111–13
USA, 25–35
risk factors, 32–4
surveillance methods, 30–2
by year of diagnosis, 25
viral infections
control, HIV and hepatitis, 151
### Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Entry</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>prognosis, 61</td>
</tr>
<tr>
<td>95-7</td>
<td>virological parameters, prognostic value, 95-7</td>
</tr>
<tr>
<td>87-9</td>
<td>virus culture, 87-9</td>
</tr>
<tr>
<td></td>
<td>as diagnostic test, drawbacks, 89</td>
</tr>
<tr>
<td>88</td>
<td>sensitivity and specificity of assays, 88</td>
</tr>
<tr>
<td>61</td>
<td>wasting syndrome, 61</td>
</tr>
<tr>
<td>86, 91</td>
<td>Western blot assay, 86, 91</td>
</tr>
<tr>
<td></td>
<td>women see HIV-infected woman; pregnancy</td>
</tr>
<tr>
<td></td>
<td>zalcitabine see didoxycytidine</td>
</tr>
<tr>
<td>206-11</td>
<td>zidovudine, 206-11</td>
</tr>
<tr>
<td>210</td>
<td>adverse affects, 210</td>
</tr>
<tr>
<td>208-11</td>
<td>in children, 208-11</td>
</tr>
<tr>
<td>224, 227</td>
<td>US paediatric treatment trials, 224, 227</td>
</tr>
<tr>
<td>213-14</td>
<td>combination therapies, 213-14</td>
</tr>
<tr>
<td>136-7</td>
<td>Concorde trial, 136-7</td>
</tr>
<tr>
<td>148</td>
<td>fetal effects, 148</td>
</tr>
<tr>
<td>216-17</td>
<td>management guidelines, 216-17</td>
</tr>
<tr>
<td>209-10</td>
<td>pregnancy trial, 209-10</td>
</tr>
<tr>
<td>13</td>
<td>reduction of vertical transmission, 13</td>
</tr>
<tr>
<td>210-11</td>
<td>resistance, 210-11</td>
</tr>
</tbody>
</table>